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PURPOSE. The graft site microenvironment has a profound effect on alloimmunity and graft
survival. We aimed to study the kinetics and phenotype of trafficking antigen-presenting cells
(APC) to the draining lymph nodes (DLNs) in a mouse model of corneal transplantation, and to
evaluate the homing mechanisms through which graft site inflammation controls APC trafficking.
METHODS. Allogeneic donor corneas were transplanted onto inflamed or quiescent graft beds.
Host- (YAeþ) and donor (CD45.1þ or eGFPþ)-derived APCs were analyzed by flow cytometry.
Protein and mRNA expression of the CC chemokine receptor (CCR)7 ligands CCL19 and
CCL21 were assessed using ELISA and Real-Time qPCR, respectively. Transwell migration
assay was performed to assess the effect of DLNs isolated from hosts with inflamed graft beds
on mature bone marrow–derived dendritic cells (BMDCs).
RESULTS. We found that inflamed graft sites greatly promote the trafficking of both recipient-
and graft-derived APCs, in particular mature CCR7þ CD11cþ dendritic cells (DC). CCL19 and
CCL21 were expressed at significantly higher levels in the DLNs of recipients with inflamed
graft beds. The supernatant of DLNs from recipients with inflamed graft beds induced a
marked increase in mature DC migration compared with supernatant from recipients with
quiescent graft beds in a transwell assay. This effect was abolished by neutralizing CCL19 or
CCL21. These data suggest that graft site inflammation increases the expression of CCR7
ligands in the DLNs, which promote mature DC homing and allorejection.
CONCLUSIONS. We conclude that the graft site microenvironment plays a critical role in
alloimmunity by determining DC trafficking through the CCR7-CCL19/21 axis.
Keywords: antigen presenting cells, migration, microenvironment, CCR7, CCL19, CCL21
Clinical and experimental findings indicate that transplantsurvival is influenced by the graft bed microenvironment,
and strategies that alter this microenvironment (e.g., suppress-
ing the host bed inflammation prior to transplantation) may
improve graft survival. This concept has received support from
earlier findings in experimental corneal transplantation that
suggest the graft site microenvironment can have a profound
effect on alloimmunity.1–3 Accordingly, corneal transplantation
into inflamed or vascularized corneal beds is recognized as a
‘high-risk’ transplant with a survival rate between 35% and 65%
in the first year,1,4–6 despite maximal use of both local and
systemic immunosuppressive drugs, while corneas transplant-
ed into quiescent graft beds yield a 2-year survival rate greater
than 90% without systemic immunosuppression,6,7 highlighting
the importance of perioperative inflammation in the develop-
ment of alloimmunity. In corneal transplantations performed in
quiescent ‘low-risk’ graft beds, the indirect sensitization
pathway is dominant8–12; however, in ‘high-risk’ inflamed graft
site, the direct pathway of sensitization becomes predominant.3
The degree and kinetics of sensitization is determined in part by
the phenotype and maturation status of antigen presenting cells
(APC).13–16 Increased allosensitization in hosts with inflamed
graft beds leads to higher graft rejection rates compared with
hosts with quiescent graft beds.17 However, the molecular
mechanisms mediating increased allosensitization and graft
rejection in inflamed hosts remain to be fully elucidated.
CC chemokine receptor (CCR) 7 knock out in donor-derived
APCs leads to reduced allosensitization18 and cell trafficking,19
suggesting a critical role of CCR7-mediated APC trafficking in
transplantations carried out in inflamed graft beds. The homing
factors for CCR7-mediated cell trafficking are CC chemokine
ligand (CCL) 19 and CCL21,20 and their expression can be
increased due to tissue inflammation.21 Thus, we hypothesize
that graft site inflammation determines the trafficking of corneal
APCs by regulating CCL19 and CCL21 expression in DLN.
In the current study, we used a murine corneal transplan-
tation model and systematically analyzed the kinetics and
phenotype of trafficking host- and donor-derived APCs at
various time points. Our results suggest that an inflamed graft
site microenvironment leads to increased expression of CCR7
ligands in the DLNs, promoting mature APCs to migrate to the
DLNs, and thus amplifying allosensitization and graft rejection.
MATERIALS AND METHODS
Mice
Six-week-old male BALB/c and C57BL/6 mice were purchased
from Charles River Laboratories (Wilmington, MA, USA). The
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eGFPþ transgenic (CByJ.B6-Tg[CAG-EGFP]1Osb/J) and CD45.1þ
transgenic (B6.SJL-PtprcaPep3b/BoyJ) mice were from Jackson
Laboratory (Bar Harbor, ME, USA). Two donor-recipient
combinations were used for tracing the trafficking APCs:
donor corneas from eGFPþmice were transplanted onto BALB/
c recipients to measure the eGFPþ donor APC trafficking;
CD45.2þ wild-type BALB/c donor grafts were transplanted to
transgenic CD45.1þ recipients to measure CD45.2þ donor
APCs, and YAeþ recipient APCs. All animals were treated in
accordance with the ARVO statement for the Use of Animals in
Ophthalmic and Vision Research, and experiments were
approved by the Institutional Animal Care and Use Committee.
Corneal Transplantation
As previously described,17,22,23 inflamed graft beds were
created by placing three intrastromal 11-0 nylon sutures
(Sharpoint; Surgical Specialties Corporation, Reading, PA,
USA) into the central cornea of recipient eye 14 days before
transplantation. These sutures reliably induce neovasculariza-
tion.22 During transplantation (day 0), a 2-mm corneal button
was harvested from the donor animal and grafted onto an
inflamed or quiescent 1.5-mm graft bed with eight interrupted
11-0 nylon sutures. Intraperitoneal ketamine (120 mg/kg) and
xylazine (20 mg/kg) were used for anesthesia with additional
perioperative subcutaneous buprenorphine (0.1 mg/kg).
Flow Cytometry
Draining lymph nodes were excised at 4, 24, 48, and 72 hours
after corneal transplantation, and 23106 cells from single cell
suspension were used for flow analysis. The CD90.2 fraction
was isolated using magnetic-activated cell sorting (MACS;
#130-094-523; Miltenyi Biotec, Auburn, CA, USA) as indicated.
After incubation in FcReceptor-blocker (R&D Systems,
Minneapolis, MN, USA), cells were incubated with following
antibodies and isotype controls (Biolegend, San Diego, CA,
USA; unless noted): FITC anti-mouse Ea52-68 peptide bound
to I-Ab (YAe, clone eBioY-Ae; eBioscience, San Diego, CA,
USA), Alexa Fluor647 anti-mouse CD3e antibody (clone 145-
2C11), PE anti-mouse CD45.1 (clone A20), Alexa Fluor488
anti-eGFP (clone A-21311; Invitrogen, Grand Island, NY, USA),
FITC and Alexa Fluor647 anti-mouse/human CD11b antibody
(clone M1/70), PECy5 and FITC anti-mouse CD11c (clone
N418; eBioscience), PE/Cy7 anti-mouse I-A/I-E antibody (MHC
II, clone M5/114.15.2), and PE anti-mouse CD197 (CCR7)
antibody (clone 4B12). Stained cells were analyzed using the
LSR II flow cytometer (BD Bioscience. San Jose, CA, USA) and
FlowJo software (Tree Star, Ash Island, OR, USA). YAe mAb
recognizes the epitope defined by donor MHC class II I-Ea 52-
68 peptide presented in the context of recipient MHC class II
I-Ad.24,25 Upon transplantation of CD45.2þ BALB/c donor
corneas to CD45.1 C57BL/6 recipients, recipient-derived cells
(I-Ad) capture and process donor MHC class II (I-E), and
present the I-Ea 52-68 peptide, thus becoming YAeþ alloan-
tigen-baring recipient-derived APCs.
RNA Isolation and Quantitative Real-Time PCR
Draining lymph nodes were snap-frozen in liquid nitrogen;
RNA was isolated using the RNeasy Mini Kit (Qiagen,
Germantown, MD, USA), and reverse transcribed using oligo
(dT) primer and SuperscriptTM III (Invitrogen). One micro-
liter of total cDNA synthesized from 400 ng of total RNA was
used for each quantitative Real-Time PCR (n¼ 6/group) with
Taqman Universal PCR Mastermix and FAM-MGB dye-labeled,
predesigned gene expression assays (Applied Biosystems,
Foster City, CA, USA) for Ccl19 (Mm00839967_g1) and Gapdh
(Mm99999915_g1). Ccl21Ser primers were synthetized ac-
cording to verified sequences (Harvard PrimerBank ID:
14547891a1). The results were analyzed using the compara-
tive threshold cycle (CT) method.
Enzyme-Linked Immunosorbent Assay
Draining lymph nodes from recipients with inflamed and
quiescent graft beds were collected 24 hours after corneal
transplantation (n ¼ 3/group), and protein was extracted in
radioimmunoprecipitation assay (RIPA) buffer containing
proteinase inhibitor cocktail (Roche, Indianapolis, IN,
USA), 10 mM NaF, and 1 mM Na3OV4 (Sigma-Aldrich Corp.,
St. Louis, MO, USA). In addition, sorted CD11cþ cells were
cultured 0.5 3 106/mL in media containing phorbol 12-
myristate 13-acetate (PMA) and ionomycin (Sigma-Aldrich
Corp.) for 24 hours in a U-bottom 96-well culture plate, and
the supernatant of the cell culture was then used for ELISA
(n ¼ 5/group). For each ELISA reaction, 1000 ng total
protein was used (concentration measured by BCA assay;
Pierce, Rockford, IL, USA) in detection kits for murine
CCL19/MIP-3b and CCL21/6Ckine (R&D Systems). Absor-
bance was determined using a POLARstar Optima plate
reader (BMG Labtech; Cary, NC).
Culture of BMDCs
Bone marrow–derived dendric cells were cultured as previ-
ously described.26 To generate mature BMDCs, immature
BMDCs were subcultured in 6-well plates with 10 ng/mL of
IFN-c (PeproTech, Rocky Hill, NJ, USA) for 48 hours.
Ex Vivo Draining Lymph Node Explant Culture
Ipsilateral DLNs from recipients with inflamed and quiescent
graft beds were collected at 24 hours after corneal transplan-
tation, and incubated with 500 lL of supplemented RPMI-
1640 medium (PMA/Ionomycin; Sigma-Aldrich Corp.) at 378C
for 24 hours. Supernatant was then collected for the
migration assays.
Transwell Migration Assay and In Vitro
Chemokine Neutralization
The BMDC migration assay was performed with transwell
inserts with polycarbonate filters (5- and 8-lm pore size for
immature BMDCs; 8 lm for mature BMDCs; Corning Life
Sciences, Tewksbury, MA, USA). Mature BMDCs at 1 3 105
were placed in the top well. As a potential source of
chemotactic stimuli, serial dilutions and/or 200 lL of DLN
culture supernatant from recipients with inflamed and
quiescent graft beds was added to each well (two indepen-
dent experiments with n ¼ 3 mice/group). Single or a
combination of neutralization antibodies against CCL19 (10
lg/mL) and CCL21 (2 lg/mL; AF880, AF457; R&D Systems)
was added to the bottom wells as indicated. Additional
control wells with matching isotypes and lipopolysaccharide
(LPS) were used. To assess a possible toxic effect of
neutralizing antibodies, we assessed cell viability using trypan
blue staining before and 4 hours after treatment with
antibodies. In a second transwell migration experiment,
mature BMDCs were stimulated with IFN-c and treated with
or without dexamethasone (107 M) and supernatant.27
Additionally, we added anti-CCL19 and anti-CCL21 at different
concentrations to determine the additive effect in suppress-
ing DC migration. After incubation for 4 hours at 378C, green
fluorescent microspheres (1 3 105/well; Dako, Carpinteria,
CA, USA) were added to each well as an internal control.
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Samples were analyzed using flow cytometry with a stopping
gate at 0.5 3 105 microsphere counts.
Statistical Analyses
Experiments with more than two groups were analyzed via 1-
or 2-way ANOVA test with post hoc Tukey’s or Bonferroni’s
multiple comparison test. Comparisons between two groups
were analyzed using the Student’s t-test. A P value of less than
0.05 was considered statistically significant. All statistical
calculations were performed using Prism Version 5.04 software
(GraphPad, La Jolla, CA, USA).
RESULTS
Inflammation in the Graft Beds Increases Homing
of Graft-Derived APCs to DLNs
In order to identify graft-derived APCs, we transplanted eGFPþ
transgenic corneal grafts (C57BL/6) onto BALB/c host beds, or
CD45.2þ grafts (BALB/c) onto transgenic CD45.1þ C57BL/6
hosts. To achieve a more distinct separation of graft cell
population, we depleted CD90.2þ lymphocytes in the eGFPþ
grafted recipient samples prior to flow cytometry analysis (Fig.
1A). In CD45.1þ recipients with CD45.2þ corneal grafts, cells
were stained with anti-CD45.2 and anti-CD3 antibodies, and
then gated on CD45.2þCD3 cells (Fig. 1C). Between 4 and 72
hours post transplantation, we observed increased frequencies
of graft-derived APCs (eGFPþ and CD45.2þ) trafficking to the
DLNs in recipients with inflamed graft beds compared with
recipients with quiescent graft beds, with a peak at 24 hours
(Figs. 1B, 1D).
Inflamed Graft Beds Enhance Homing of Recipient
Alloantigen-Bearing APCs to DLNs
After transplantation of CD45.2þ Balb/c corneas into inflamed
or quiescent graft beds of CD45.1þC57BL/6 hosts, we detected
recipient alloantigen-bearing APCs (CD3YAeþ) in DLNs using
flow cytometry (Fig. 1E). Recipients with inflamed graft beds
displayed significantly higher frequencies of CD3YAeþ cells in
the DLNs than recipients with quiescent graft beds as early as 4
hours; this was sustained until 48 hours post grafting, and
slightly decreased at 72 hours, while the frequencies of
CD3YAeþ cells in recipients with quiescent graft beds
progressively increased between 4 and 72 hours (Fig. 1F).
Inflamed Graft Beds Increase MHC IIþCCR7þ DC
Homing to the DLNs
Next, we analyzed the expression of MHC II and CCR7 on
trafficking eGFPþ graft-derived and YAeþ host-derived APCs
to the DLNs 24 hours post transplantation (Fig. 2). The total
cell count of eGFPþ and YAeþ cells was increased in the DLNs
of recipients with inflamed graft beds (Figs. 2A, 2B).
Transplantations into inflamed graft beds led to a significant
increase of MHC IIþCCR7þ cells of both eGFPþ (Figs. 2C, 2D)
and YAeþ (Figs. 2E, 2F) cells in the DLNs compared with
transplantations into quiescent graft beds. Further analysis
of CD11c and CD11b expression on APCs revealed that the
frequencies of both CD11cþCD11b Langerhans cells and
CD11cþCD11bþ DCs were increased among eGFPþ graft-
derived APCs (Figs. 2G–I), and the frequencies of
CD11cþCD11bþ DCs among YAeþ host-derived APCs were
significantly increased in the DLNs of recipients with
inflamed graft beds (Figs. 2J–L).
CCL19 and CCL21 Expression are Upregulated in
DLNs After Transplantation Into Inflamed Graft
Beds
We assessed mRNA expression of a series of chemokines
including CCL1, CCL2, CCL19, and CCL21, and CXCL13, and
found that the CCR7 ligands CCL19 and CCL21 were
significantly upregulated in the DLNs of recipients with
inflamed graft beds (Fig. 3A), while their expression levels in
other lymphoid tissues such as the spleen and thymus were
comparable in both conditions (Supplementary Material S1).
Using ELISA assays, we found that the protein levels of the
CCR7 ligands in the DLNs of recipients with inflamed graft
beds were significantly higher than in the DLNs of recipients
with quiescent graft beds. No significant difference was
detected between na¨ıve mice and recipients with quiescent
graft beds (Fig. 3B).
CD11cþ Dendritic Cells in Inflammation
Contribute to the Enhanced Secretion of CCL19
and CCL21 in DLNs
We first analyzed the maturation status of total CD11cþ cells,
and found that CD11cþ DCs from recipients with inflamed
graft beds displayed higher frequencies of MHC IIhi cells and an
overall increased level of MHC II protein expression compared
to DCs from recipients with quiescent graft beds (Fig. 3C).
After sorting CD11cþ DCs from the DLNs of recipients with
inflamed and quiescent graft beds, we cultured these cells for
24 hours under stimulation, and then measured the protein
level of CCL19 and CCL21 in the culture supernatant using
ELISA. We found that CD11cþ cells from DLNs of recipients
with inflamed graft beds secreted significantly higher amounts
of both CCL19 and 21 than CD11cþ cells from recipients with
quiescent graft beds (Fig. 3D).
Increased CCL19 and CCL21 Secretion Selectively
Recruits More Mature Dendritic Cells In Vitro
To evaluate the chemotactic ability of secreted factors from the
DLNs after transplantation, we used mature BMDCs in a
transwell migration assay, and assessed the number of migrated
cells toward the supernatant from DLNs of recipients with
inflamed versus quiescent graft beds. Culture supernatant of
DLNs explanted from the recipients with inflamed graft beds
significantly increased the numbers of migrating mature
BMDCs (Supplementary Material S2B). Next, we determined
mature BDMC migration after neutralization of CCL19 or
CCL21 with murine antibodies in the supernatant of recipients
with inflamed graft beds. Both CCL19 and CCL21 neutraliza-
tion alone or in combination reduced BMDC migration
compared with BMDCs with supernatant only (Fig. 4A).
Because cell viability before and after the assay was similar in
all groups (>97%), reduced cell numbers are due to decreased
migration and not cell death. Mature BMDCs used in this
transwell assay exhibited higher levels of CCR7 and MHC II
compared with immature BMDCs (Fig. 4B).
Because immunosuppressive treatment is known to inhibit
DC maturation,28 we next determined whether the blockade of
CCL19 and CCL21 can alter the response to immunosuppres-
sion with dexamethasone, a commonly used corticosteroid in
humans. We used the transwell system and analyzed the
migration potential of BMDCs after immunosuppression with
dexamethasone in combination with or without neutralizing
CCL19 and CCL21. As expected, dexamethasone alone
significantly decreased the number of migrated BMDCs.
Moreover, additional treatment with anti-CCL19 and anti-
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FIGURE 1. Kinetics of trafficking host- and donor-derived APCs to the DLN. Allogeneic donor corneas were transplanted into the recipients had
inflamed or quiescent graft beds. Inflamed graft beds were created by placing intrastromal corneal sutures. Single cell suspensions from the DLNs of
recipients were analyzed at various time points post transplantation using flow cytometry. (A) To assess donor-derived APCs, corneas of eGFPþ
C57BL/6 were transplanted onto BALB/c mice with inflamed or quiescent graft beds. Representative analysis shows eGFPþ donor-derived APCs in
the lymph nodes at 24 hours post operation. To exlude donor-derived T cells, CD90.2þ cells were depleted before flow cytometry analysis. Cell
numbers, 4 hours: 4.4 6 0.1 vs. 4.5 6 0.08; 24 hours: 4.4 6 0.1 vs. 4.4 6 0.1; 48 hours: 4.4 6 0.08 vs. 4.3 6 0.08; and 72 hours: 4.6 6 0.03 vs. 4.5
6 0.1 (3106/sample). (B) Frequencies of eGFPþ donor cells at 4, 24, 48, and 72 hours in the DLNs after corneal transplantation are shown (**P <
0.001, ***P < 0.0001, n¼ 3/group, 2-way ANOVA, Bonferroni post test, 13 106 events/sample). (C) To assess donor-derived APCs, CD45.2þ BALB/c
donors were transplanted onto transgenic CD45.1þ C57BL/6 mice with inflamed or quiescent graft beds. Representative analysis shows CD45.2þ
CD3 donor-derived APCs in the lymph nodes at 24 hours post operation. Cell numbers, 4 hours: 7.96 0.2 vs. 8.16 0.3; 24 hours: 8.26 0.2 vs. 8.0
6 0.1; 48 hours: 8.0 6 0.004 vs. 8.0 6 0.1; and 72 hours: 8.0 6 0.004 vs. 8.0 6 0.003 (3106/sample) (D) Frequencies of CD45.2þCD3 donor APCs
at 4, 24, 48, and 72 hours in the DLNs after corneal transplantation are shown (*P < 0.05, n¼ 3/group, 2-way ANOVA, Bonferroni post test, 13106
events/sample). (E) To assess alloantigen-bearing host-derived APCs, cells were stained for YAe expression in transgenic CD45.1þ C57BL/6 hosts
who had received CD45.2þ BALB/c donor corneas. To exclude T cells, the cells were stained for CD3 expression. Representative analysis shows
host-derived YAeþCD3 APCs distributed in lymph nodes at 24 hours post transplantation. Cell numbers, 4 hours: 7.9 6 0.2 vs. 8.1 6 0.1; 24 hours:
8.1 6 0.2 vs. 8.1 6 0.2; 48 hours: 8.0 6 0.2 vs. 8.0 6 0.2; and 72 hours: 8.0 6 0.1 vs. 8.1 6 0.1 (3106/sample). (F) Frequencies of YAeþCD3 cells
at 4, 24, 48, and 72 hours after corneal transplantation are shown (Values are expressed as mean 6 SEM, *P < 0.05, **P < 0.01, ***P < 0.001; n¼ 4,
2-way ANOVA, Bonferroni post test, 13 106 events/sample). Representative results from at least three repeats at each time point.
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CCL21 further decreased cell migration in a dose-dependent
manner (Fig. 4C).
DISCUSSION
Inflammation at transplant site determines allorecognition.3
We aimed to investigate whether allorecognition is mediated
through regulating mature APC trafficking via the CCR7-
CCL19/21 axis. The importance of APC trafficking has been
shown in various transplantation settings,25,29,30 and studies in
corneal transplantation suggest that inflamed graft beds are
associated with enhanced trafficking of APCs to lymphoid
tissue.1,23 However, most studies reported their findings at a
single time point that varies from study to study, and very little
is known about the mechanisms how the graft site microen-
vironment regulates APC trafficking. The inflammatory cyto-
kines TNF-a and IL-1 have been shown to promote DC
maturation and allosensitization,31 and blocking these cyto-
kines improves graft survival.32–35 Dendritic cell homing is
mostly dependent on CCR7,36 and mature DCs express CCR7
by which they sense CCL21 gradients, allowing them to
migrate to lymphatic vessels, both in steady state and in
inflammation.37 To clarify previous findings, and determine a
FIGURE 2. Phenotypic analysis of donor-derived APCs in DLNs at 24 hours post transplantation. Total cell numbers of (A) eGFPþ donor-derived
(50.28 6 6.83 vs. 116.1 6 14.05 [3103/sample], n¼ 3, P¼ 0.0103, t-test) and (B) YAeþ host-derived cells (26.17 6 0.89 vs. 57.03 6 8.07 [3103/
sample], n¼ 3, P¼ 0.0094, t-test) in DLNs are shown 24 hours after transplantation. (C) Representative dot plot graph showing trafficking eGFPþ
cells analyzed for CCR7 and MHC II expression in the DLNs of recipients with inflamed and quiescent graft beds using flow cytometry. (D)
Frequencies of MHC IIþCCR7þ donor-derived cells in the lymph nodes of recipients with inflamed graft beds compared with recipients with
quiescent graft beds are shown (72.2 6 1.6 vs. 41.8 6 2.3%, n¼ 3/group, ***P < 0.0001, Student’s t-test). (E) Representative dot plot graph shows
trafficking host-derived YAeþ cells analyzed for CCR7 and MHC II expression in the DLNs of recipients with inflamed and quiescent graft beds using
flow cytometry. (F) Frequencies of MHC IIþCCR7þ host-derived cells in the lymph nodes of recipients with inflamed graft beds compared with
recipients with quiescent graft beds are shown (34.7 6 2.6 vs. 43.9 6 0.9%, n¼ 3/group, *P¼ 0.03, Student’s t-test). (G) Representative dot plot
graph showing eGFPþ donor-derived cells from recipient lymph nodes analyzed for CD11b and CD11c expression. (H) Frequencies of
CD11cþCD11b donor-derived dendritic cells in the lymph nodes of recipients with inflamed and quiescent graft beds are shown (29.1 6 4.3 vs.
45.9 6 3.0%, n ¼ 3/group, *P ¼ 0.03, Student’s t-test). (I) Frequencies of CD11cþCD11bþ donor-derived dendritic cells in the lymph nodes of
recipients with inflamed and quiescent graft beds are shown (12.2 6 1.3 vs. 21.7 6 2.6%, n ¼ 3/group, *P ¼ 0.03, Student’s t-test). (J)
Representative dot plot graph showing YAeþ host-derived cells from recipient lymph nodes analyzed for CD11b and CD11c expression. (K)
Frequencies of CD11cþCD11b host-derived dendritic cells in the lymph nodes of recipients with inflamed and quiescent graft beds are shown (72.0
6 2.5 vs. 65.6 6 1.0%, n ¼ 3/group, n.s. P ¼ 0.08, Student’s t-test). (L) Frequencies of CD11cþCD11bþ host-derived dendritic cells in the lymph
nodes of recipients with inflamed and quiescent graft beds are shown (11.0 6 0.6 vs. 19.17 6 0.9%, n¼ 3/group, **P¼ 0.0017, Student’s t-test).
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suitable time point to analyze the homing mechanisms, we
performed a systematic analysis of the kinetics and magnitude
of the trafficking APCs in high-risk recipients with inflamed
graft beds versus low-risk recipients with quiescent graft beds.
Our results indicate that the CCR7 ligands CCL19 and CCL21
are significantly upregulated in DLNs of high-risk recipients
and are principally involved in promoting graft site APC
trafficking to host lymphoid tissues, thus amplifying allorecog-
nition.
Previous studies have mainly used MHC II allopeptides (I-
Ad or I-Ab) to identify recipient- and donor-derived APCs.
There are significant limitations with this method, because
the expression levels of MHC II vary dramatically depending
on cell type and maturation; I-Adþ cells in a BALB/c recipient
do not all present alloantigens; and in normal donor
APCs,1,23,28 I-Ab is highly expressed only after inflammatory
stimulation in corneal DCs.38 Here, we used YAe staining
(YAeþCD3) to detect recipient APCs bearing alloantigen,
which identifies the recipient MHC II molecules that bear
processed donor I-Ea 52-68 peptide.25 Further, we used eGFPþ
or CD45.2þ grafts to trace donor-derived APCs. We observed
significantly higher frequencies of recipient- and donor-
derived APCs in the DLNs of recipients with inflamed graft
beds than quiescent graft beds. The increase of trafficking
APCs observed in our study confirms previous findings in
high-risk recipients,3 and further suggests that the increased
APC frequencies may lead to higher allosensitization. In
addition, the kinetics and magnitude of trafficking APCs in
recipients with quiescent graft beds was consistent with
previous reports in corneal and other organ transplantation
models at the respective time points.25,29,30
We further focused on these cells for phenotypic analyses
and observed that the frequencies of mature MHC IIþCCR7þ
and CD11cþCD11b DCs were significantly higher in the DLNs
of recipients with inflamed graft beds, suggesting that
inflammation leads to a selective recruitment of mature DCs
to the DLNs. The increase of mature DCs in the DLNs of
recipients with inflamed graft beds strongly indicates their role
in enhancing allosensitization and graft rejection. The higher
frequencies of CCR7þ APCs in the DLNs after transplantation
into inflamed graft beds also suggest that CCR7 plays a critical
role in homing of these cells to the DLNs. In fact, we observed
a significant increase of mRNA and protein expression for both
CCR7 ligands, CCL19 and CCL21, in recipients with inflamed
graft beds, suggesting that trafficking of mature DCs from the
inflammatory graft site to the DLNs is mediated through their
increased secretion. In inflammation, lymphotoxin alpha/beta,
and TNF are known to upregulate CCL19 and CCL21
FIGURE 2. Continued.
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FIGURE 3. Transplantation in inflamed graft beds enhances CCL19 and CCL21 secretion in the lymph nodes and dendritic cells. (A) The mRNA
expression of Ccl1, Ccl2, Ccl19, Ccl21, and Cxcl13 in lymph nodes of recipients with inflamed and quiescent graft beds was quantified at 24 hours
post transplantation using Real-Time qPCR (**P < 0.01, ***P < 0.001; n¼ 6/group, 2-way ANOVA, Bonferroni post test). A primer pair designed for
Ccl21Ser was used here, because murine lymph nodes only express CCL21Ser.58 (B) Protein expression of CCL19, CCL21, and CCL2 in the lymph
nodes of recipients with inflamed and quiescent host beds as well as na¨ıve mice was measured in tissue lysates using ELISA 24 hours post
transplantation. (CCL19: 1356 6 94 vs.1065 6 18 and 971.7 6 63 pg/mg total protein, n¼ 3/group, P¼ 0.008, CCL21: 475.5 6 25.8 vs. 223.1 6
45.8 and 278.4 6 18.0 pg/mg total protein, n¼ 3/group, ***P¼ 0.0007, 1-way ANOVA with post hoc Tukey’s test, *P < 0.05, **P < 0.001, ***P <
0.0001). (C) Representative flow cytometry analysis showing MHC II expression of sorted CD11cþ cells of DLNs of recipients with inflamed and
quiescent graft beds 24 hours after transplantation (n¼6/group). (D) Protein expression of CCL19 and CCL21 of sorted CD11cþ cells was measured
by ELISA 24 hours post transplantation. CD11cþ cells isolated from lymph nodes of recipients with inflamed and quiescent graft beds were cultured
with PMA and ionomycin and the supernatant was collected after 24 hours (CCL19: 1612 6 17 vs. 2430 6 34, n¼ 5/group, ***P < 0.0001; CCL21:
220.7 6 3.3 vs. 336.2 6 7.4, n ¼ 5/group, ***P < 0.0001).
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FIGURE 4. Increased CCL19 and CCL21 expression in lymph nodes of recipients with inflamed graft beds promotes mature dendritic cell migration.
(A) For the transwell migration assay 200 lL supernatant of cultured lymph nodes isolated from recipients with inflamed graft beds were added to
the bottom well as a chemoattractant, and mature BMDCs were added to the upper well. Neutralizing antibodies against CCL19 (10 lg/mL) and/or
CCL21 (2 lg/mL) were added as indicated (data show results from one out of two experiments with 3 mice/each group; Student’s t-test). (B)
Representative flow cytometry analysis showing CD11c, CCR7, and MHC II expression of mature and immature BMDCs used in the transwell assay
(data from one out of three independent experiments are shown). (C) Transwell migration assay with mature BMDCs cultured with supernatant
from lymph nodes of recipients with inflamed graft beds. Bone marrow–derived dendritic cells were stimulated with IFN-c with or without
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production.39–43 Mature DCs can alter the secretion of
chemokines in high endothelial venules (HEV) and fibroblastic
cells, and DC-derived lymphotoxins are important for recruit-
ment of trafficking cells.44,45 It has been debated whether
under inflammation, trafficking DCs might be a direct source of
chemokines in the DLNs.46 In our model, enhanced expression
of CCL19 and CCL21 was associated with increased frequen-
cies of graft-derived CD11cþ cells and mature CD11cþMHC IIþ
cells in recipients with inflamed graft beds. Sorted and cultured
CD11cþ cells from the DLNs of recipients with inflamed graft
beds secreted significantly higher amounts of CCL19 and
CCL21, demonstrating that these DCs directly contribute to the
increased CCR7-ligand expression in an inflamed environment.
Clinically, recognized high-risk factors for corneal allograft
rejection, such as history of infection or other inflammatory
conditions,1,47–49 may promote allosensitization through en-
hanced APC trafficking.50 Therefore, we propose that targeting
mature APC homing through the CCR7-CCL19/21 axis is a
potential strategy to reduce graft rejection in high-risk corneal
transplantation.
To determine the functional consequences of upregulated
CCR7 ligands in the DLNs, we examined the migration of
BMDCs toward the supernatant of cultured DLNs from
transplant recipients in a transwell migration assay. A
significantly greater number of mature BMDCs migrate toward
the supernatant collected from DLNs of recipients with an
inflamed graft bed than with quiescent graft beds (Supple-
mentary Material S2), and this difference was abolished by
blocking CCL19 or CCL21 alone or in combination (Fig. 4A);
additionally, serial dilutions of the conditioned media demon-
strated a clear dose response in the inflammatory state but no
clear trend in the quiescent state (Supplementary Material S2).
These results indicate that both CCL19 and CCL21 are involved
in enhancing the chemotaxis of mature DCs. Previously, a
series of investigations reported that the chemokines CCL19
and CCL21 are preferentially expressed depending on the cell
type and disease condition.51 High endothelial venules of
lymph nodes highly express CCL21.52,53 Stromal cells in the
area surrounding HEVs express CCL19, which is then
transported to the lumen of HEVs.53 Based on our observation
that the expression of CCR7 on immature DCs was low (Fig.
4B), we speculate that DLNs from recipients with inflamed
graft beds selectively recruit mature DCs through expressing
high levels of CCR7 ligands (Fig. 3).
Although immunosuppressive agents are used widely to
treat inflamed graft beds, in so-called ‘high-risk’ corneal
transplantation, they have numerous side effects, and
allorejection remains a substantial clinical problem. We thus
performed a series of experiments to determine whether
blockade of CCL19 and CCL21 has any additive effect in
suppressing DC maturation and function beyond the effect of
corticosteroids. Our data show that treatment of BMDCs with
dexamethasone decreased their migratory capacity (Figs. 4).
Moreover, we observed that blockade of CCL19 and CCL21
further decreased the migration of BMDCs compared with
dexamethasone alone (Fig. 4C). Dexamethasone and other
immunosuppressive agents have been shown successful in
treating transplant rejection.28 Here, we employed dexameth-
asone as an example of a broad-spectrum anti-inflammatory
drug demonstrating that immunosuppression is effective in
preventing DC migration. In a previous study we have
blocked CCL21 via subconjunctival injection of anti-CCL21
antibody after corneal transplantation and found 40% less
CD11cþ cells in the DLNs.54 Furthermore, it is known that
systemic blockade of the CCL19/21-CCR7 axis not only
suppresses inflammatory but also immunoregulatory respons-
es.55,56 We have thus chosen not to systemically neutralize
CCL19 and CCL21 in transplant recipients, because it will
effectively interfere regulatory T-cell function.56,57
In summary, our results demonstrate that inflammation at
the transplant site promotes trafficking of both recipient- and
graft-derived APCs, especially mature CCR7þCD11cþ DCs, to
host lymphoid tissues. Enhanced APC trafficking is due to
increased CCL19 and CCL21 secretion in DLNs. The data
establish the CCR7-CCL19/21 axis as a key mechanism
connecting graft site inflammation with enhanced allosensiti-
zation and exacerbated transplant rejection. These results
suggest that it is essential to consider the local graft bed
inflammatory microenvironment and employ measures that
promote local graft bed quiescence to optimize allograft
survival.
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